Activist 3i Proposes $9M Rescue Financing and Board Overhaul at Valion Bio
VBIO sits 30% above its 52-week low of $0.251 on elevated volume (2.3× avg).
Summary
3i, LP proposes a $9 million investment in Valion Bio, contingent on replacing the CEO, removing the Chair, and taking control of the board — a dramatic escalation of its activist campaign amid the company's deepening financial crisis.
Key Events · Ownership and Investor Activity · VBIO
-
$9M Investment Proposal with Strings Attached
3i, LP proposes to invest up to $9 million in Series B or Series C Preferred Stock — $3 million at closing, $6 million in installments — subject to due diligence, definitive agreements, continued Nasdaq listing, and execution of a Board-approved plan.
-
Demand for Immediate CEO Termination
3i reiterates its demand that CEO Michael Handley be terminated immediately, a condition of the proposed investment.
-
Board Overhaul Demanded
3i demands Chair Sheryle Bolton step down, Maier Tarlow become Chairman, and two additional 3i-nominated directors join the board, effectively giving 3i control.
-
Financing Tied to Nasdaq Listing and Plan Adherence
Each installment of the $6 million is conditioned on Valion Bio maintaining its Nasdaq listing and adhering to a strategic plan approved by the reconstituted board.
Analysis · VBIO · Life Sciences
Escalating its activist campaign, Valion Bio's largest shareholder, 3i, LP, has proposed a $9 million preferred stock investment — $3 million immediately and $6 million in installments — contingent on the immediate termination of CEO Michael Handley, the removal of Chair Sheryle Bolton, and the installation of 3i's Maier Tarlow as Chairman plus two additional 3i-nominated directors. The proposal arrives just days after 3i's initial demand for Handley's ouster and against a backdrop of severe financial distress: a going-concern warning, a net loss of $6.2 million in Q1 2026, and a pending reverse stock split vote. While the financing would provide critical runway, it comes at the cost of ceding control to an activist investor — a high-stakes governance battle that could determine the company's survival.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.25 to $5.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.